Cytotoxic bispecific monoclonal antibody, its production and use
US5217713A · kind A · utility
21Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 1992 |
| Grant date | Jun 8, 1993 |
| Priority date | — |
| Expiry date | Feb 27, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses, a bispecific monoclonal antibody to an ansamitocin derivative and a target antigen, particularly tumor-associated antigen, which can carry an ansamitocin derivative in a stable and inactive form at other sites than the target and release the active-form ansamitocin derivative at the target site, so that an anticancer agent having excellent durability and selectivity with little adverse action can be prepared using the bispecific monoclonal antibody and ansamitocin derivatives.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.